Sparta Biopharma Announces US Commercial Availability of BioEnthesis™ for Rotator Cuff Repair
News provided by
Share this article
Share this article
DURHAM, N.C. and MADISON, N.J., March 9, 2021 /PRNewswire/ -- Sparta Biopharma, Inc., a privately-held company, developing osteobiologics for sports medicine announces the availability of BioEnthesis
TM, the first-of-its-kind allograft that has both mineralized and demineralized layers which provide the requisite properties for healing and repair within the rotator cuff.  According to the Healthcare Cost and Utilization Project, there are more than 4.5 million physician visits per year for rotator cuff pain and dysfunction.
Osteobiologics have been used successfully over the last several decades. These allografts have facilitated the formation of functional bone tissue and the healing of bone. In that time, hundreds of allograft compositions and forms have served patients across multiple orthopedic ailments. However, their potential to recreate and regenerate bone at the intersection of soft and hard-tissue had not been fully explored. Sparta has combined insights from biology, pharmaceutical sciences, and tissue engineering to develop BioEnthesis for the repair and reconstruction of bone within the rotator cuff enthesis.

Related Keywords

Dimitrios Angelis , Adam Yanke , Dushyanth Surakanti , Sparta Biopharma Inc , , Sparta Biopharma , Healthcare Cost , Utilization Project , Scientific Advisory Board , Assistant Professor , Midwest Orthopedics , Good Tissue , Inc , Health Care Amp Hospitals , Medical Equipment , Medical Pharmaceuticals , General Sports , டிமிட்ரியோஸ் தேவதூதர்கள் , ஆடம் யாங்கே , சுகாதாரம் செலவு , பயன்பாடு ப்ராஜெக்ட் , உதவியாளர் ப்ரொஃபெஸர் , மிட்வெஸ்ட் எலும்பியல் , நல்ல திசு , இன்க் , ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் , மருத்துவ உபகரணங்கள் , மருத்துவ மருந்துகள் , ஜநரல் விளையாட்டு ,